- Trials with a EudraCT protocol (10,987)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
10,987 result(s) found.
Displaying page 170 of 550.
| EudraCT Number: 2013-004851-19 | Sponsor Protocol Number: AAPSMCS1002 | Start Date*: 2014-07-29 |
| Sponsor Name:ACORN Research, LLC | ||
| Full Title: A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma. | ||
| Medical condition: Surgically unresectable or metastatic chondrosarcoma | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-003702-33 | Sponsor Protocol Number: RG_14-150 | Start Date*: 2015-01-23 | |||||||||||||||||||||
| Sponsor Name:University of Birmingham | |||||||||||||||||||||||
| Full Title: IMPRESS-AF: IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation | |||||||||||||||||||||||
| Medical condition: Atrial fibrillation with preserved left ventricular systolic function and normal levels of the brain natriuretic peptide. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2015-000273-13 | Sponsor Protocol Number: | Start Date*: 2015-03-19 |
| Sponsor Name:University Hospitals of North Midlands NHS Trust | ||
| Full Title: Mobilisation of endothelial progenitor cells by statin therapy in patients with coronary disease: a proof of concept pilot study. | ||
| Medical condition: 1. New onset angina 2. Acute coronary syndromes (ACS) to include ST elevation ACS and None ST elevation ACS | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-001534-18 | Sponsor Protocol Number: Aes-103-003 | Start Date*: 2013-08-07 | |||||||||||
| Sponsor Name:AesRx | |||||||||||||
| Full Title: A Phase 2, Exploratory, Placebo-Controlled, Multicenter, Double-Blind Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Five Dose Regimens of Aes-103 Given for 2... | |||||||||||||
| Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-001615-13 | Sponsor Protocol Number: 1 | Start Date*: 2015-07-31 | |||||||||||
| Sponsor Name:Imperial College London | |||||||||||||
| Full Title: TARGETING OF THE SMALL AIRWAYS IN PATIENTS WITH COPD: AIRWAY EFFECTS OF TIOTROPIUM -Respimat vs. Handihaler | |||||||||||||
| Medical condition: Chronic Obstructive Pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-001736-38 | Sponsor Protocol Number: Academed100215 | Start Date*: 2015-08-26 |
| Sponsor Name:Hull and East Yorkshire Hospitals NHS trust | ||
| Full Title: The utility of feNO in the differential diagnosis of chronic cough: The response to anti-inflammatory therapy with prednisolone and montelukast | ||
| Medical condition: Chronic cough is a common and poorly diagnosed condition. Younger patients tend to receive a diagnosis of asthma, whereas older patients are increasingly identified has having gastroesophageal refl... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-005323-27 | Sponsor Protocol Number: IM101-344 | Start Date*: 2015-09-16 | ||||||||||||||||
| Sponsor Name:University of Michigan | ||||||||||||||||||
| Full Title: A phase II study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis—a double-blind, placebo-controlled, randomized controlled trial | ||||||||||||||||||
| Medical condition: Diffuse Cutaneous Systemic Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2014-001453-17 | Sponsor Protocol Number: PVO-1A-201 | Start Date*: 2015-07-07 | |||||||||||
| Sponsor Name:Clementia Pharmaceuticals Inc. | |||||||||||||
| Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects with Fibrodysplasia O... | |||||||||||||
| Medical condition: Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and abnormal heterotopic ossificat... | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-005814-12 | Sponsor Protocol Number: UCL10/0470 | Start Date*: 2013-08-19 | |||||||||||
| Sponsor Name:University College London | |||||||||||||
| Full Title: Phase II, randomised, placebo controlled, multicentre, feasibility study of low dose (metronomic) cyclophosphamide with or without nintedanib (BIBF 1120) in advanced ovarian cancer (METRO-BIBF) | |||||||||||||
| Medical condition: Advanced ovarian cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-018596-24 | Sponsor Protocol Number: 6311 | Start Date*: 2011-05-19 |
| Sponsor Name:Oxford Radcliffe Hospital NHS Trust | ||
| Full Title: Assessment of Salmonella Typhim Vi(TM) vaccine (Sanofi Pasteur MSD) for the investigation of selective antibody deficiency to polysaccharide. | ||
| Medical condition: Suspected primary antibody deficiency states will be investigated | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-000501-52 | Sponsor Protocol Number: PARAGON2011 | Start Date*: 2011-12-07 | ||||||||||||||||
| Sponsor Name:Greater Glasgow and Clyde [...] | ||||||||||||||||||
| Full Title: PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms | ||||||||||||||||||
| Medical condition: Patients with potentially hormone responsive recurrent or metastatic gynaecological cancers from following subgroups: A - Epithelial ovarian cancer, primary peritoneal cancers and cancers of the fa... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: GB (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2019-000695-41 | Sponsor Protocol Number: 67953964MDD2001 | Start Date*: 2019-06-27 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV | |||||||||||||
| Full Title: A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Subjects with Ma... | |||||||||||||
| Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-004065-27 | Sponsor Protocol Number: TTP488-303 | Start Date*: 2018-03-19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:vTv THERAPEUTICS LLC | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Open Label Extension Study For Continued Safety And Efficacy Evaluation Of Azeliragon In Patients With Mild Alzheimer's Disease | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: MILD ALZHEIMER'S DISEASE | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2008-002627-90 | Sponsor Protocol Number: 3589 | Start Date*: 2008-09-05 |
| Sponsor Name:Royal Liverpool and Broadgreen University Hospitals NHS Trust [...] | ||
| Full Title: Intracellular boosting of HIV protease inhibitors through inhibition of transport - a novel strategy for potentiating HIV therapy | ||
| Medical condition: This study is to evaluate the intracellular boosting effect of furosemide and dipyridamole of the HIV protease inhibitors in HIV positive patients. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-002564-27 | Sponsor Protocol Number: STH16037 | Start Date*: 2013-01-31 |
| Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | ||
| Full Title: Pilot open study of testosterone replacement in non-alcoholic steatohepatitis | ||
| Medical condition: Non alcoholic fatty liver disease (NAFLD) in men with low serum testosterone levels | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2017-000619-17 | Sponsor Protocol Number: NAXIVA1.0 | Start Date*: 2017-08-02 | ||||||||||||||||
| Sponsor Name:Common Services Agency (CSA) | ||||||||||||||||||
| Full Title: Phase II neoadjuvant study of Axitinib for reducing extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion. | ||||||||||||||||||
| Medical condition: Venous tumour thrombus in clear cell renal cell cancer with venous invasion | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2012-003947-31 | Sponsor Protocol Number: | Start Date*: 2016-12-30 | |||||||||||
| Sponsor Name:Oxford University Hospitals NHS Trust | |||||||||||||
| Full Title: Optimising Renal outcome in Myeloma renal failure A pilot study of Thalidomide, Bendamustine, and Dexamethasone (TBD) vs Bortezomib, Bendamustine, and Dexamethasone (BBD) in patients with renal fa... | |||||||||||||
| Medical condition: Myeloma and renal impairment | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-002223-10 | Sponsor Protocol Number: | Start Date*: 2015-02-11 |
| Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust | ||
| Full Title: A randomised controlled trial of a new daily skincare regimen for lowering the incidence of pinsite infections following circular frame surgery | ||
| Medical condition: Pinsite infection | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-003455-61 | Sponsor Protocol Number: 2013GR06 | Start Date*: 2015-02-11 | |||||||||||
| Sponsor Name:Tayside Academic Sciences Centre | |||||||||||||
| Full Title: Perindopril and Leucine to improve muscle function in older people | |||||||||||||
| Medical condition: Sarcopenia | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-004686-28 | Sponsor Protocol Number: 14143JK-AS | Start Date*: 2018-07-16 |
| Sponsor Name:Belfast Health and Social Care Trust (BHSCT) | ||
| Full Title: A randomised, double-blind, placebo-controlled trial to evaluate the effect of Epstein-Barr virus suppression in chronic obstructive pulmonary disease (EViSCO trial). | ||
| Medical condition: Epstein-Barr virus infection in patients with chronic obstructive pulmonary disease. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.